Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
Abstract Objective Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH...
Main Authors: | Takahiro Kambara, Rei Shibata, Yuusuke Sakamoto, Teruhiro Sakaguchi, Hiroyuki Osanai, Yoshihito Nakashima, Hiroshi Asano, Toyoaki Murohara, Masayoshi Ajioka |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13104-024-06726-7 |
Similar Items
-
Natriuretic peptides and C‐reactive protein in in heart failure and malnutrition: a systematic review and meta‐analysis
by: Konstantinos Prokopidis, et al.
Published: (2024-10-01) -
Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta‐analysis
by: Stefanie Hendricks, et al.
Published: (2022-10-01) -
Performance of the Abbott Architect Immuno-Chemiluminometric NT-proBNP Assay
by: Chin-Shern Lau, et al.
Published: (2022-05-01) -
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population
by: Stefano Ciardullo, et al.
Published: (2022-11-01) -
Clinical correlation between N-terminal pro-b-type natriuretic peptide and angiographic coronary atherosclerosis
by: Demóstenes G.L. Ribeiro, et al.
Published: (2014-06-01)